Stock Notes

Lupin

Every Finvezto stock note on Lupin, dated and newest first. Coverage spans pharma.

1 note and counting
25 May 2026
Lupin received Chinese regulatory approval for Oseltamivir Phosphate Oral Suspension, an antiviral for influenza treatment.
China is a high-volume antiviral market. This adds a new geographic revenue stream to Lupin's branded generic portfolio.

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.